emfizz.com
emfizz.com May 23, 2017


Coherus Biosciences Inc (CHRS) Receives $40.50 Average PT from Analysts

19 May 2017, 11:23 | Jan Cross

Why This Humira Patent Loss Might Not Be What You Think

ABBV EPS Estimates for Fiscal Year Chart

Heading into the stock price potential, Coherus Biosciences, Inc. needs to grow just 68.07% to cross its median price target of $40. The brokerage now has a buy rating on the biotechnology company's stock.

Other research analysts have also issued research reports about the company. BMO Capital Markets began coverage on Coherus Biosciences in a report on Friday, May 5th. Zacks Investment Research lowered Coherus Biosciences from a "buy" rating to a "hold" rating in a report on Thursday, February 16th. Baird reaffirmed an outperform rating and set a $40.00 price target on shares of Coherus Biosciences in a research note on Wednesday, February 1st. Finally, Maxim Group reaffirmed a "buy" rating and set a $43.00 target price on shares of Coherus Biosciences in a report on Tuesday, March 14th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. BMO Capital Markets now has a $54.00 price objective on the biotechnology company's stock. Shares of Coherus Biosciences (NASDAQ:CHRS) traded down 1.007% on Monday, reaching $22.125. The stock price recently experienced a 5-day gain of 11.21% with 1.19 average true range (ATR). The mean rating score for this stock is at 1.80. For the past month, Coherus Biosciences, Inc.'s stock has been 31.37%, 6.52% for the last quarter, -14.04% for the past six months and 25.71% for the past 52 weeks.

Coherus Biosciences (NASDAQ:CHRS) last announced its quarterly earnings results on Monday, May 8th. Analysts are forecasting earnings of $-1.4 on a per share basis this quarter. The firm had revenue of $0.16 million during the quarter. In our current pick, Coherus Biosciences, Inc. If you are accessing this news story on another website, it was stolen and reposted in violation of USA & worldwide trademark and copyright legislation. The original version of this news story can be read at https://transcriptdaily.com/2017/05/19/coherus-biosciences-inc-chrs-pt-set-at-38-00-by-citigroup-inc.html.

Candriam Luxembourg S.C.A. purchased a new stake in shares of Coherus Biosciences during the third quarter valued at $5,115,000. The stock closing price is now trading upward to its 50 day moving average with change of 14.09%, escalated to its 20 day moving average with figure of 18.17% and behind its 200 day moving average with value -8.59%. Following the transaction, the insider now owns 90,452 shares in the company, valued at $1,875,069.96. The sale was disclosed in a legal filing with the SEC, which is available at this link. The company's stock had a trading volume of 330,948 shares.

TPK hikes 3D Touch price for iPhone with OLED, says paper
To this point, Goldman Sachs analyst Simona Jankowski provided the following component cost breakdown for the iPhone 8 last week. The iPhone 8 is believed to have an edge-to-edge OLED display that completely removes the top and bottom bezels up front.


Syria condemns attack by US-led coalition
Russia's deputy foreign minister Gennady Gatilov added to the condemnation, calling the strike "a breach of Syrian sovereignty". A road between Iraq and Syria would facilitate the flow of assistance from Iran , which is a strong backer of Assad.


Maria Sharapova responds to French Open denial: Nothing can stop my dreams
But nevertheless Roland Garros invests a lot - along with the other Grand Slams, the ATP , and the WTA - into the fight against doping.


Several institutional investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System now owns 14,589 shares of the biotechnology company's stock valued at $411,000 after buying an additional 130 shares during the period. BlueCrest Capital Management Ltd bought a new position in shares of Coherus Biosciences during the first quarter worth about $246,000. FMR LLC boosted its position in shares of Coherus Biosciences by 17.2% in the first quarter. Endurant Capital Management LP acquired a new position in shares of Coherus Biosciences during the third quarter valued at about $225,000. The company's stock had a trading volume of 321,424 shares. BlackRock Fund Advisors now owns 1,389,802 shares of the biotechnology company's stock worth $37,219,000 after buying an additional 121,067 shares in the last quarter.

Yet another important factor while evaluating a good buy/sell decision for Coherus Biosciences, Inc.

To be clear, the hurdle for any biosimilar company to launch a biosimilar-Humira by 2019 is still high, and given AbbVie's extensive patent estate extending into the 2030's, any biosimilar challenger must be willing to undertake an at-risk launch until further patents are invalidated through the IPR process or the Federal Circuit Courts.



Other News

Trending Now

Donald Trump's advisors 'contacted Russian officials at least 18 TIMES before election'
The newspaper said Comey was in the Oval Office that day with other national security officials for a terrorism threat briefing. The Flynn investigation was part of a broader probe into Russian interference in 2016's presidential election.

CytRx (CYTR) Earning Positive Press Coverage, Report Finds
Maximum and minimum EPS estimate for the current quarter is projected at $-0.5 and $-0.5, respectively, according to 1 analysts. Currently Cytrx Cp (NASDAQ:CYTR)'s shares owned by insiders are 1.7%, whereas shares owned by institutional owners are 17.5%.

Find My Device: new name and features for Google's Android Device Manager
You can ask the app anything from weather to Cricket score and other useful data which you want to ask to a person. Instead, the Assistant will pull the relevant details from information you've previously shared with Google .

Trump Denies Pressuring Comey to End Flynn Probe
In the memo, which ABC News has not seen, Comey wrote that he was asked by the president to let the Flynn probe go in February. Meanwhile, at home, other investigations into Russian Federation will move forward.

Donald Trump says he could name Federal Bureau of Investigation head by next week
A late and somewhat unlikely addition to Trump's short list, Lieberman is nonetheless the sudden frontrunner. Mr Lieberman lost his 2006 Democratic primary bid but won Senate re-election as a third-party candidate.

Download Android 'Oreo' Beta from Google now
The next version of Android is all about making interactions easier and improving the core performance of smartphones and apps . It may even be possible to sync your refrigerator with your phone so the AI will be able to send you a grocery list wirelessly.

Mourinho walks out of interview after loss to Spurs
Smalling, Jones, Mata - it is very important for them to play 90 minutes". "I think he deserves another chance". Manchester United have entered the UEFA Europa League Final after beating Celta Vigo 2-1 in the semi-final.

Julian Assange says will not forgive or forget after Sweden drops investigation
She accused him of having sex with her as she slept without using a condom despite repeatedly having denied him unprotected sex. Ny told a news conference in Stockholm: "He has tried to dodge all attempts to avoid Swedish and British legal authorities".

WannaCry virus infects 48000 computer systems in India
Estimates of the economic impact are still being tabulated, but they could easily run into the tens of billions of dollars. The organization's files will remain encrypted unless it pays ransomware in bitcoin ranging from $300 to $600.

President Trump to embark on first foreign trip as president
United States officials had warned that acting now could end the President's hopes of reigniting the Middle East peace process. In Trump, however, many Saudis see a decisive, business-focused leader, who they say shares their goals in the region.